

PROGEN Biotechnik GmbH now with new joint leadership

Heidelberg, Germany, 15.05.2019 – PROGEN Biotechnik GmbH, established manufacturer of premium antibodies, has announced the succession of its former General Manager Dr. Sven Kuhlendahl who died last November. Since April first, Katja Betts and Maik Lander have been leading the company as equals.

Katja Betts holds an EMSc in Communications Management and a BA (Hons) in Communications. She has gathered management experience in the life science sector at the non-profit organization EMBO and while working as European Marketing Manager for a laboratory equipment distributor. As Head of Marketing she has been responsible for PROGEN's focus on new markets since 2016 and has been instrumental in expanding the company's international business during this time. Ms. Betts is looking forward to the new tasks ahead: "Our focus in the near future will be on the development of existing and new markets in collaboration with international partners."

Maik Lander holds a graduate degree in Biotechnology and Chemical Technology Engineering. His academic education was followed by many years of experience in process development in biotechnology manufacturing, amongst others at ReliaTech GmbH, a specialist for growth factors and antibodies. In 2016 he joined PROGEN as Head of Production and is now committed to the responsibilities ahead: "We will concentrate on novel, customer-oriented product developments that provide a competitive edge in protein detection, quantification and purification."

Maik Lander and Katja Betts both worked closely with former General Manager Sven Kuhlendahl and intend to continue the successful management of the thriving company in joint leadership – together with an excellent and tight-knit team. In these new roles, Ms. Betts will primarily oversee all market-relevant areas while Mr. Lander will assume responsibilities for the entire product development and manufacturing process.

About PROGEN

Founded in 1983 as one of the first biotechnology companies in Germany, PROGEN Biotechnik GmbH is now an established manufacturer and supplier of research antibodies and immunological test systems for the global life science community. PROGEN's antibodies are among the most published antibodies in biomedical and cell biology literature. Building on its core-competency in immunochemistry, the ISO 13485 certified company has expanded its collaborations and business in recent years to access new research markets with innovative immunological products for protein detection, quantification and purification. Special focus lies on the development of ELISA test systems for the determination of adeno-associated virus (AAV) titers in gene therapeutic research and development. PROGEN places great value on premium quality and is breaking new ground in product validation to meet the key demand of the research community for high quality, reliable immunochemicals. Since 2012, Heidelberg-based PROGEN has been a 100% subsidiary of R-Biopharm AG.

Press contact

Katja Betts

Managing Director

Phone: +49 6221 8278-0

E-Mail: betts@progen.com

Image caption



PROGEN's new Managing Director duo, Katja Betts and Maik Lander will continue the growth course of the company.

© PROGEN Biotechnik GmbH